coteau ARQ.

AVLN

Avalyn Pharma Inc.
$26.04
−$1.21 (4.44%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-25%-9%+6%+21%+36%Apr 30Oct 23Jul 2752w high $40.1752w low $22.24
AVLNSPY
Wall St. Highest PT $80.00 (+207.2%) Wall St. Avg PT $61.80 (+137.3%)
$23$42$61$80$100POC $28Hi $80Avg $62
Underwater Drawdown %Max DD -40.6%Current -33.7%
0.0%-40.6%
Relative Strength vs SPY-18.0% vs SPYUnderperforming
+33%0%-33%
1W
+$2.38 (10.06%)
1M
−$3.63 (12.23%)
3M
−$1.91 (6.83%)
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.40
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$26.04
Average target$61.80
+$35.76 (+137.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$52.00
Median$61.80
High$80.00
12-month Wall Street target range
Recent analyst rating changes · 5
Initiated
2026-10-02 · Raymond James started covering AVLN at Outperform
Reiterated
2026-08-13 · Morgan Stanley reiterated Overweight on AVLN
Initiated
2026-05-26 · Evercore ISI Group started covering AVLN at Outperform
Initiated
2026-05-26 · Guggenheim started covering AVLN at Buy
Initiated
2026-05-26 · Morgan Stanley started covering AVLN at Overweight
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$1.2B
P/E (next 12 months, estimated)-10.1
52-week range$22.24 – $40.17
Dividend yieldNo dividend
Analyst consensusStrong Buy (5)
Average analyst price target$61.80 (+137%)

What they do

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for AVLN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

AVLN earningsNext report in 22 days
Next report
Mon Nov 16, 2026Before the open
EPS consensus-$0.75 range -$0.79–-$0.71
Revenue consensus$0 3 analysts
Last 2 quarters · EPS vs estimate
Aug 12, 2026-$0.98est -$0.56−73.5%Below estimates
Jun 3, 2026-$21.83est -$0.81−2578.5%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 03:14:00 ET
26-0626-08-21.830.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
Barrons.com · Oct 13
Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey
Simply Wall St. · Sep 23
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
GlobeNewswire · Sep 21
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
GlobeNewswire · Sep 16
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · Sep 08
Rating changes
Initiated
2026-10-02 · Raymond James started covering AVLN at Outperform
Reiterated
2026-08-13 · Morgan Stanley reiterated Overweight on AVLN
Initiated
2026-05-26 · Evercore ISI Group started covering AVLN at Outperform
Initiated
2026-05-26 · Guggenheim started covering AVLN at Buy
Initiated
2026-05-26 · Morgan Stanley started covering AVLN at Overweight

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 03:14:00 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026